Navigation Links
Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
Date:11/27/2012

g even if successfully developed and approved  Tarix's development of PanCyte.  These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to, the risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements after the date of this release.

For Investors & Media:
Joshua Drumm, Ph.D. / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com


'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Unigene to Announce Third Quarter 2012 Financial Results on November 20, 2012
2. Unigene To Present at the 2012 Obesity Societys 30th Annual Scientific Meeting
3. Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
4. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
5. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
6. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
7. Unigene to Present at TIDES 2012
8. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
9. Edison Pharmaceuticals Closes $20M Series F Financing
10. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
11. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... (Pink Sheets: MDBX ) ( www.thedispensingsolution.com ), ... to MDBX.  The company previously announced that their name ... The company is a leader in the design, manufacture ... The free-standing unit features 60 or more slots that ...
... 2011 This year, the melanoma community saw the first ... This major step forward will give more than 400 party-goers ... Gala.  They will gather at the Trump National Golf Club ... these cutting-edge advances and raise money for future research through ...
Cached Medicine Technology:MedBox Announces Ticker Symbol Change 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 3
(Date:12/26/2014)... The Biofeedback Federation of Europe annual meeting ... Rome, Italy and is hosted by the Salesian Pontifical ... a wide variety of topics such as ADHD, anxiety, ... in athletes. The scientific program will feature the latest ... allows clients to see what is going on in ...
(Date:12/26/2014)... PA (PRWEB) December 26, 2014 Pentec ... Work in the state of Pennsylvania for 2014. The ... first statewide programs of its kind in the country. ... Foundation, the Pennsylvania Department of Community and Economic Development, ... Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... - Company to Webcast Presentation at 9:30 a.m. ET on ... Corporation,(Nasdaq: SMTS ) is scheduled to participate in the ... 22, 2008 at the New York Hilton., Bruce J. ... presentation that will be webcast live on Wednesday,May 21, 2008 ...
... have used cough medicine for children younger than two ... effective for children in this age group, an Australia-first ... and Royal Childrens Hospital study, surveyed 325 parents at ... care centres about their use of over-the-counter medication for ...
... The International Association for Dental Research (IADR) ... winners of the annual IADR/GSK Innovation in Oral ... innovative oral care technologies that may maintain and ... Sharing the $225,000 unrestricted research grant, which is ...
... 2008 Canadian researchers have shown that an electric ... neurologic and neuropsychological symptoms in humans. , Following ... and behavioral aftereffects, such as memory loss and symptoms ... grant from Hydro-Qubec and conducted by clinicians from the ...
... 15, 2008 Physicians and dentists should collaborate to ... or may develop osteoporosis, say researchers in the cover ... the American Dental Association. , The authors of the ... the medical and dental literature to examine osteoporosis effect ...
... with ICG-Guided Therapy On Over 76,000+ ... ... 15 CardioDynamics (Nasdaq:,CDICD), the innovator and leader of Impedance ... today,announced the presentation of a significant independent ICG clinical study,at ...
Cached Medicine News:Health News:Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference 2Health News:Study finds parents use cough medicines on under-2s despite the warnings 2Health News:IADR and GlaxoSmithKline Consumer Healthcare announce winners 2Health News:IADR and GlaxoSmithKline Consumer Healthcare announce winners 3Health News:Electric shocks can cause neurologic and neuropsychological symptoms 2Health News:CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting 2Health News:CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting 3
Cushing-Hopkins periosteal elevator, Gutsch handle, blade width 7/16" (11 mm), length 7 5/8" (194 mm)....
Barr periosteal elevators....
Seldin periosteal elevators....
Williger periosteal elevators....
Medicine Products: